Cargando…

Evaluation of Innotrac Aio! Second-Generation Cardiac Troponin I Assay: The Main Characteristics for Routine Clinical Use

The availability of a simple, sensitive, and rapid test using whole blood to facilitate processing and to reduce the turnaround time could improve the management of patients presenting with chest pain. The aim of this study was an evaluation of the Innotrac Aio! second-generation cardiac troponin I...

Descripción completa

Detalles Bibliográficos
Autores principales: Hedberg, P., Valkama, J., Suvanto, E., Pikkujämsä, S., Ylitalo, K., Alasaarela, E., Puukka, M.
Formato: Texto
Lenguaje:English
Publicado: 2006
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1903460/
https://www.ncbi.nlm.nih.gov/pubmed/17671616
http://dx.doi.org/10.1155/JAMMC/2006/39325
_version_ 1782133959651491840
author Hedberg, P.
Valkama, J.
Suvanto, E.
Pikkujämsä, S.
Ylitalo, K.
Alasaarela, E.
Puukka, M.
author_facet Hedberg, P.
Valkama, J.
Suvanto, E.
Pikkujämsä, S.
Ylitalo, K.
Alasaarela, E.
Puukka, M.
author_sort Hedberg, P.
collection PubMed
description The availability of a simple, sensitive, and rapid test using whole blood to facilitate processing and to reduce the turnaround time could improve the management of patients presenting with chest pain. The aim of this study was an evaluation of the Innotrac Aio! second-generation cardiac troponin I (cTnI) assay. The Innotrac Aio! second-generation cTnI assay was compared with the Abbott AxSYM first-generation cTnI, Beckman Access AccuTnI, and Innotrac Aio! first-generation cTnI assays. We studied serum samples from 15 patients with positive rheumatoid factor but with no indication of myocardial infarction (MI). Additionally, the stability of the sample with different matrices and the influence of hemodialysis on the cTnI concentration were evaluated. Within-assay CVs were 3.2%–10.9%, and between-assay precision ranged from 4.0% to 17.2% for cTnI. The functional sensitivity (CV = 20 %) and the concentration giving CV of 10% were approximated to be 0.02 and 0.04, respectively. The assay was found to be linear within the tested range of 0.063–111.6 μ g/L. The correlations between the second-generation Innotrac Aio!, Access, and AxSYM cTnI assays were good (r coefficients 0.947–0.966), but involved differences in the measured concentrations, and the biases were highest with cTnI at low concentrations. The second-generation Innotrac Aio! cTnI assay was found to be superior to the first-generation assay with regard to precision in the low concentration range. The stability of the cTnI level was best in the serum, lithium-heparin plasma, and lithium-heparin whole blood samples (n = 10 , decrease < 10 % in 24 hours at +20(°)C and at +4(°)C. There was no remarkable influence of hemodialysis on the cTnI release. False-positive cTnI values occurred in the presence of very high rheumatoid factor values, that is, over 3000 U/L. The 99th percentile of the apparently healthy reference group was ≤ 0.03   μ g/L. The results demonstrate the very good analytical performance of the second-generation Innotrac Aio! cTnI assay.
format Text
id pubmed-1903460
institution National Center for Biotechnology Information
language English
publishDate 2006
record_format MEDLINE/PubMed
spelling pubmed-19034602007-08-01 Evaluation of Innotrac Aio! Second-Generation Cardiac Troponin I Assay: The Main Characteristics for Routine Clinical Use Hedberg, P. Valkama, J. Suvanto, E. Pikkujämsä, S. Ylitalo, K. Alasaarela, E. Puukka, M. J Autom Methods Manag Chem Research Article The availability of a simple, sensitive, and rapid test using whole blood to facilitate processing and to reduce the turnaround time could improve the management of patients presenting with chest pain. The aim of this study was an evaluation of the Innotrac Aio! second-generation cardiac troponin I (cTnI) assay. The Innotrac Aio! second-generation cTnI assay was compared with the Abbott AxSYM first-generation cTnI, Beckman Access AccuTnI, and Innotrac Aio! first-generation cTnI assays. We studied serum samples from 15 patients with positive rheumatoid factor but with no indication of myocardial infarction (MI). Additionally, the stability of the sample with different matrices and the influence of hemodialysis on the cTnI concentration were evaluated. Within-assay CVs were 3.2%–10.9%, and between-assay precision ranged from 4.0% to 17.2% for cTnI. The functional sensitivity (CV = 20 %) and the concentration giving CV of 10% were approximated to be 0.02 and 0.04, respectively. The assay was found to be linear within the tested range of 0.063–111.6 μ g/L. The correlations between the second-generation Innotrac Aio!, Access, and AxSYM cTnI assays were good (r coefficients 0.947–0.966), but involved differences in the measured concentrations, and the biases were highest with cTnI at low concentrations. The second-generation Innotrac Aio! cTnI assay was found to be superior to the first-generation assay with regard to precision in the low concentration range. The stability of the cTnI level was best in the serum, lithium-heparin plasma, and lithium-heparin whole blood samples (n = 10 , decrease < 10 % in 24 hours at +20(°)C and at +4(°)C. There was no remarkable influence of hemodialysis on the cTnI release. False-positive cTnI values occurred in the presence of very high rheumatoid factor values, that is, over 3000 U/L. The 99th percentile of the apparently healthy reference group was ≤ 0.03   μ g/L. The results demonstrate the very good analytical performance of the second-generation Innotrac Aio! cTnI assay. 2006 /pmc/articles/PMC1903460/ /pubmed/17671616 http://dx.doi.org/10.1155/JAMMC/2006/39325 Text en Copyright © 2006 P. Hedberg et al. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Hedberg, P.
Valkama, J.
Suvanto, E.
Pikkujämsä, S.
Ylitalo, K.
Alasaarela, E.
Puukka, M.
Evaluation of Innotrac Aio! Second-Generation Cardiac Troponin I Assay: The Main Characteristics for Routine Clinical Use
title Evaluation of Innotrac Aio! Second-Generation Cardiac Troponin I Assay: The Main Characteristics for Routine Clinical Use
title_full Evaluation of Innotrac Aio! Second-Generation Cardiac Troponin I Assay: The Main Characteristics for Routine Clinical Use
title_fullStr Evaluation of Innotrac Aio! Second-Generation Cardiac Troponin I Assay: The Main Characteristics for Routine Clinical Use
title_full_unstemmed Evaluation of Innotrac Aio! Second-Generation Cardiac Troponin I Assay: The Main Characteristics for Routine Clinical Use
title_short Evaluation of Innotrac Aio! Second-Generation Cardiac Troponin I Assay: The Main Characteristics for Routine Clinical Use
title_sort evaluation of innotrac aio! second-generation cardiac troponin i assay: the main characteristics for routine clinical use
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1903460/
https://www.ncbi.nlm.nih.gov/pubmed/17671616
http://dx.doi.org/10.1155/JAMMC/2006/39325
work_keys_str_mv AT hedbergp evaluationofinnotracaiosecondgenerationcardiactroponiniassaythemaincharacteristicsforroutineclinicaluse
AT valkamaj evaluationofinnotracaiosecondgenerationcardiactroponiniassaythemaincharacteristicsforroutineclinicaluse
AT suvantoe evaluationofinnotracaiosecondgenerationcardiactroponiniassaythemaincharacteristicsforroutineclinicaluse
AT pikkujamsas evaluationofinnotracaiosecondgenerationcardiactroponiniassaythemaincharacteristicsforroutineclinicaluse
AT ylitalok evaluationofinnotracaiosecondgenerationcardiactroponiniassaythemaincharacteristicsforroutineclinicaluse
AT alasaarelae evaluationofinnotracaiosecondgenerationcardiactroponiniassaythemaincharacteristicsforroutineclinicaluse
AT puukkam evaluationofinnotracaiosecondgenerationcardiactroponiniassaythemaincharacteristicsforroutineclinicaluse